Literature DB >> 17606713

Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma.

Bruce Elliott1, Richard A Scolyer, Stefan Suciu, Serge Lebecque, Donata Rimoldi, Oliver Gugerli, Elena Musat, Raghwa N Sharma, Danielle Lienard, Ulrich Keilholz, Alessandro Testori, Alexander Eggermont, Rona MacKie, Caroline Robert, Martin Cook, John F Thompson, Eric Angevin, Alain Spatz.   

Abstract

PURPOSE: In a previous immunohistochemical study of dendritic cells (DC) in sentinel lymph nodes (SLN) draining regressing melanomas, we found that the accumulation of mature DC-LAMP(+) DCs in SLNs was associated with local expansion of antigen-specific memory effector CTLs and the absence of metastasis in downstream lymph nodes. The aim of this study was to investigate the prognostic importance of the maximal density of mature DCs in SLNs. EXPERIMENTAL
DESIGN: A total of 458 consecutive patients with micrometastatic melanoma within SLNs were eligible for analysis. The maximal density of mature DC-LAMP(+) DCs was evaluated by three independent observers and categorized into three classes (<100, 100 to <200, and >or=200/mm(2)).
RESULTS: There was excellent interobserver reproducibility for maximum density of mature DC-LAMP(+) DC scores (kappa score = 0.82). There were differences in the maximal density scores and staining intensity according to the treating melanoma center (P < 0.001). The higher the mature DC density in the SLN is, the longer is the duration of survival [P = 0.047; hazard ratio, 0.70; 95% confidence interval, 0.50-1.00]. Adjusted by thickness and ulceration, the prognostic importance of DC density was lower (P = 0.36).
CONCLUSION: This study is the first to report the prognostic value of DC-LAMP(+) DC counts in SLNs containing metastatic melanoma. Patients with a high density of mature DCs (>or=200/mm(2)) have the lowest risk of death. It also provides evidence that a lack of maturation in the SLNs is important in biological facilitation of melanoma progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17606713     DOI: 10.1158/1078-0432.CCR-07-0358

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  20 in total

Review 1.  Enhancement of dendritic cells as vaccines for cancer.

Authors:  Meghan E Turnis; Cliona M Rooney
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

Review 2.  Molecular pathology of cutaneous melanoma.

Authors:  Léon C van Kempen; Margaret Redpath; Caroline Robert; Alan Spatz
Journal:  Melanoma Manag       Date:  2014-12-04

3.  Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas.

Authors:  Daniëlle Verver; Vichnou Poirier-Colame; Gorana Tomasic; Khadija Cherif-Rebai; Dirk J Grunhagen; Cornelis Verhoef; Stefan Suciu; Caroline Robert; Laurence Zitvogel; Alexander M M Eggermont
Journal:  Oncoimmunology       Date:  2019-09-06       Impact factor: 8.110

4.  IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity.

Authors:  Meghan E Turnis; Xiao-Tong Song; Adham Bear; Aaron E Foster; Stephen Gottschalk; Malcolm K Brenner; Si-Yi Chen; Cliona M Rooney
Journal:  J Immunol       Date:  2010-09-03       Impact factor: 5.422

Review 5.  The anticancer immune response: indispensable for therapeutic success?

Authors:  Laurence Zitvogel; Lionel Apetoh; François Ghiringhelli; Fabrice André; Antoine Tesniere; Guido Kroemer
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

6.  1alpha,25-Dihydroxyvitamin D(3) to skew intratumoral levels of immune inhibitory CD34(+) progenitor cells into dendritic cells.

Authors:  Jonathan S Kulbersh; Terry A Day; M Boyd Gillespie; M Rita I Young
Journal:  Otolaryngol Head Neck Surg       Date:  2009-02       Impact factor: 3.497

7.  Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

Authors:  Paolo A Ascierto; Antonio M Grimaldi; Nicolas Acquavella; Lorenzo Borgognoni; Luana Calabrò; Natale Cascinelli; Alessandra Cesano; Michele Del Vecchio; Alexander M Eggermont; Mark Faries; Soldano Ferrone; Bernard A Fox; Thomas F Gajewski; Jérôme Galon; Sacha Gnjatic; Helen Gogas; Mohammed Kashani-Sabet; Howard L Kaufman; James Larkin; Roger S Lo; Alberto Mantovani; Kim Margolin; Cornelis Melief; Grant McArthur; Giuseppe Palmieri; Igor Puzanov; Antoni Ribas; Barbara Seliger; Jeff Sosman; Peter Suenaert; Ahmad A Tarhini; Giorgio Trinchieri; Fernando Vidal-Vanaclocha; Ena Wang; Gennaro Ciliberto; Nicola Mozzillo; Francesco M Marincola; Magdalena Thurin
Journal:  J Transl Med       Date:  2013-06-03       Impact factor: 5.531

8.  Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis.

Authors:  Nicolas Jacquelot; María Paula Roberti; David P Enot; Sylvie Rusakiewicz; Michaela Semeraro; Sarah Jégou; Camila Flores; Lieping Chen; Byoung S Kwon; Christophe Borg; Benjamin Weide; François Aubin; Stéphane Dalle; Holbrook Kohrt; Maha Ayyoub; Guido Kroemer; Aurélien Marabelle; Andréa Cavalcanti; Alexander Eggermont; Laurence Zitvogel
Journal:  J Invest Dermatol       Date:  2016-01-29       Impact factor: 8.551

Review 9.  Biomarkers in melanoma.

Authors:  H Gogas; A M M Eggermont; A Hauschild; P Hersey; P Mohr; D Schadendorf; A Spatz; R Dummer
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

10.  The clinicopathological and gene expression patterns associated with ulceration of primary melanoma.

Authors:  Rosalyn Jewell; Faye Elliott; Jonathan Laye; Jérémie Nsengimana; John Davies; Christy Walker; Caroline Conway; Angana Mitra; Mark Harland; Martin G Cook; Andy Boon; Sarah Storr; Sabreena Safuan; Stewart G Martin; Karin Jirström; Håkan Olsson; Christian Ingvar; Martin Lauss; Tim Bishop; Göran Jönsson; Julia Newton-Bishop
Journal:  Pigment Cell Melanoma Res       Date:  2014-10-01       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.